Home Tags Drug Approvals

Tag: Drug Approvals

Aimovig (erenumab-aooe) has been approved by the U.S. Food and Drug Administration to prevent migraine headaches in adults.

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo
Doptelet (avatrombopag) has been approved by the U.S. Food and Drug Administration to treat adults with chronic liver disease who are slated to have a medical or dental procedure.

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure
Lucemyra (lofexidine hydrochloride) has been approved by the U.S. Food and Drug Administration to treat symptoms of opioid withdrawal.

FDA Approves Non-Opioid Treatment for Opioid Withdrawal

Lucemyra is an oral selective alpha 2-adrenergic receptor agonist
Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first "biosimilar" to the anemia drugs Epogen and Procrit.

FDA Approves ‘Biosimilar’ Drug to Treat Certain Types of Anemia

Retacrit is biosimilar to the drugs Epogen and Procrit
The U.S. Food and Drug Administration has expanded its approval of the multiple sclerosis drug Gilenya (fingolimod) to include children aged 10 and older.

FDA Expands Use of MS Drug to Include Children

Gilenya is the first multiple sclerosis drug approved for children
The U.S. Food and Drug Administration has approved the new Hemospray device to help control bleeding of the gastrointestinal (GI) tract.

FDA Permits Marketing of New Device for Treating GI Bleeding

Hemospray is an aerosolized spray that delivers a mineral blend to the bleeding site
Two anti-cancer drugs administered together have been approved by the U.S. Food and Drug Administration to treat BRAF-positive anaplastic thyroid cancer.

FDA Approves Drug Combo for Aggressive Thyroid Cancer

Dabrafenib + trametinib approved to treat BRAF-positive anaplastic thyroid cancer
Women are well-represented in some cardiovascular disease clinical trials

Women’s Representation in CVD Drug Trials Varies

Representation in desired range for hypertension, atrial fibrillation but low for heart failure, CAD
Ultragenyx Pharmaceutical Inc.'s Crysvita (burosumab-twza) has been approved by the U.S. Food and Drug Administration to treat adults and children ages 1 year and older with x-linked hypophosphatemia.

FDA Approves First Drug for Rare Form of Rickets

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia
The U.S. Food and Drug Administration has approved the first contact lenses that automatically darken in bright light

FDA Approves First Auto-Darken Contact Lenses

Acuvue Oasys contact lenses with light-adaptive technology are soft contact lenses made for daily use